News
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 (see chart 2). Lilly’s edge rests on a more effective drug, better execution, keener pricing and a stronger pipeline.
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the ...
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
Patients taking Eli Lilly’s drug to combat obesity, Zepbound, lost more weight than those who took Novo Nordisk’s Wegovy in a ...
Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.
In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.
A new film from Eli Lilly sounds like a recruitment ad, but it doubles as a brand manifesto to showcase the pharmaceutical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback